CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.

ABSTRACT:

Objective

To assess the relationship between CD56(bright) natural killer (NK) cells and multiple sclerosis (MS) disease activity in patients with relapsing-remitting MS treated with daclizumab high-yield process (DAC HYP).

Methods

Data were from patients enrolled in a 52-week randomized, double-blind, placebo-controlled study of DAC HYP and its extension study. Assessments included relationships of CD56(bright) NK cell numbers (identified using fluorescence-activated cell sorting) at weeks 4 and 8 with the numbers of new or newly enlarging T2-hyperintense lesions between weeks 24 and 52 and the annualized relapse rate.

Results

In DAC HYP-treated patients but not placebo-treated patients, the numbers of CD56(bright) NK cells increased over 52 weeks of treatment, and th

SUBMITTER: Elkins J 

PROVIDER: S-EPMC4309527 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature